RESULTS
DISEASE
There were 2,639 patients with CIC in the combined trials (plecanatide 3 mg [n = 877], plecanatide 6 mg [n = 877], and placebo [n = 885]). The baseline demographic and clinical characteristics were comparable among the 3 patient groups (Table Demographic and baseline disease characteristicsBMI, body mass index; CSBM, complete spontaneous bowel movement; SBM, spontaneous bowel movement.Intention-to-treat population.Percentage of patients with durable overall CSBM response for total population and by subgroup. *When grouped by select baseline characteristics, a significantly greater percentage of patients treated with 3 mg of plecanatide were durable overall CSBM responders for most subgroups (Figure In the overall population, the LSM change from baseline in the weekly number of CSBMs at week 12 was significantly improved with 3 mg of plecanatide (Δ 2.6) and 6 mg of plecanatide (Δ 2.6) vs placebo (Δ 1.5; Change from baseline in (